Glaukos Corp. ( (GKOS) ) has released its Q2 earnings. Here is a breakdown of the information Glaukos Corp. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company that specializes in developing innovative therapies for glaucoma, corneal disorders, and retinal diseases. The company is known for pioneering Micro-Invasive Glaucoma Surgery (MIGS) and continues to expand its portfolio with novel, dropless platform technologies.
In its latest earnings report for the second quarter of 2025, Glaukos Corporation announced record net sales of $124.1 million, marking a 30% increase year-over-year. The company also raised its 2025 net sales guidance to between $480 million and $486 million, reflecting confidence in its strategic growth plans.
Key financial highlights include a significant increase in glaucoma-related sales, particularly in the U.S., where sales rose by 45% year-over-year. The company’s gross margin improved to approximately 78%, with a non-GAAP gross margin of 83%. Despite a net loss of $19.7 million, this represents a notable improvement from the $50.5 million loss in the same quarter of the previous year.
Glaukos continues to invest in its pipeline, with research and development expenses increasing by 6% to $36.5 million. The company ended the quarter with $278.6 million in cash and cash equivalents, short-term investments, and no debt, positioning it well for future growth.
Looking ahead, Glaukos remains focused on executing its strategic plans and advancing its pipeline of innovative therapies. The management’s outlook suggests continued growth and development in the ophthalmic sector, with an emphasis on improving patient outcomes through cutting-edge technologies.